Leishmaniasis: Preventing And Treating A Complex Disease

Leishmaniasis is a parasitic disease caused by the bite of infected sand flies. It affects people in tropical and subtropical regions, causing skin sores and, in severe cases, affecting internal organs. There is currently no human vaccine for leishmaniasis, and prevention relies on protecting oneself from sand fly bites. However, several vaccines are in development, and some traditional practices, such as leishmanization, have shown efficacy in preventing the disease. This involves inoculation with live Leishmania to induce mild cutaneous leishmaniasis and prevent future dangerous infections.

Characteristics and values pertaining to protection measures and vaccines for leishmaniasis

Explore related products

Pentavalent: Webster's Timeline History, 1926 - 2007

$28.95

Sb Organoantimony Compounds: Part 5: Compounds of Pentavalent Antimony with Three, Two and One Sb-C Bonds (Gmelin Handbook of Inorganic and Organometallic Chemistry - 8th edition)

$549.99

Sb Organoantimony Compounds Part 4: Compounds of Pentavalent Antimony with Three Sb-C Bonds (Gmelin Handbook of Inorganic and Organometallic Chemistry - 8th edition)

$54.99

Preventative measures: protect against sand fly bites

Leishmaniasis is a parasitic disease caused by an infection with Leishmania parasites, which are spread by the bite of infected sand flies. There are no vaccines or drugs to prevent leishmaniasis. Therefore, the best way to prevent infection is to take preventive measures against sand fly bites.

Preventive measures to protect against sand fly bites include:

• Wear long-sleeved shirts and long pants when outdoors, especially during dawn and dusk when sand flies are most active. Treat clothing and gear with permethrin, an insecticide that can be used on clothing and gear, such as boots, pants, socks, and tents. Alternatively, purchase pre-treated clothing.
• Use insect repellent on exposed skin. Repellents containing DEET, picaridin, IR3535, oil of lemon eucalyptus (OLE), or para-menthane-diol (PMD) are effective. Follow the instructions on the product label for proper use.
• Sleep under an insecticide-treated bed net if sleeping outdoors or in a room that is not well-screened.
• Reduce exposure to sand flies by avoiding areas with standing water, open sewers, or other breeding sites. Keep your living area clean and free of garbage to reduce sand fly breeding sites.
• Install or repair window and door screens to keep sand flies out of homes and other buildings.

It is important to note that even if you have had leishmaniasis before, you can get it again. Therefore, it is crucial to continue taking preventive measures to protect yourself from sand fly bites.

Vaccines for dogs: immunity provided

Leishmaniasis is a parasitic disease caused by an infection with Leishmania parasites, which are spread by the bite of infected sand flies. There are no vaccines or drugs to prevent it in humans. However, there are a few vaccines for dogs that have been successful in providing immunity.

The recent preventive vaccination of dogs in Brazil has led to a reduction in the incidence of canine and human disease. In 2008, a vaccine for dogs was launched in Brazil, known as LeishTech, a recombinant protein-based vaccine. The dog vaccines are successful in providing immunity.

Leishmanization, the practice of inoculation with live Leishmania to induce mild cutaneous leishmaniasis (CL) to prevent future dangerous infection, has informed the development of a leishmaniasis vaccine. Attempts to create a vaccine with live, inactivated, or attenuated Leishmania have failed. However, attempts to create a peptide, DNA, or protein vaccine have shown efficacy in animal vaccine models.

The development of a vaccine using CRISPR-Cas9 technology was published in 2020, showing that inoculation with a live attenuated Leishmania major strain induces durable protection, analogous to leishmanization. Another gene deletion mutant was created in a Leishmania mexicana strain in 2022, showing complete inhibition of the typical cutaneous lesions in mouse models.

Several experimental infection trials have demonstrated that it is possible to induce a protective response experimentally. Many strategies for inducing immunity against Leishmania infection have been tested in murine models, with varying degrees of success.

The observation that dogs naturally infected by L. infantum could develop a protective response to the disease was proof of the concept that the induction of immune protection against canine leishmaniasis was feasible. Dogs that develop cell-mediated immunity typically do so early in the infection, although some dogs with a positive LST result do develop clinical leishmaniasis.

First-generation vaccines developed for humans have also been tested against canine ZVL. Dogs vaccinated with autoclaved L. major promastigote lysate (ALM) and BCG showed an in vitro lymphocyte proliferative response, while dogs immunized with ALM and saponin expressed a main humoral antibody response against L. infantum.

Multiple formulations of these ‘second-generation’ vaccines, as well as other preclinical vaccination strategies, have been shown to successfully generate Leishmania-specific cells that exhibit characteristics of memory Th1 cells.

Human vaccines: none available yet

Leishmaniasis is a parasitic disease caused by an infection with Leishmania parasites, which are spread by the bite of infected sand flies. It is a neglected tropical disease (NTD) that affects people in tropical and subtropical regions worldwide. There are several different forms of leishmaniasis, the most common being cutaneous leishmaniasis (CL), which causes skin sores. Other forms include mucosal leishmaniasis (ML), which can cause sores in the nose, mouth, or throat, and visceral leishmaniasis (VL), which affects the internal organs and can be deadly if left untreated.

Currently, there are no vaccines available to prevent leishmaniasis in humans. The best way to prevent infection is to protect oneself from sand fly bites. However, this is challenging due to the global presence of Leishmania infections in 98 countries across all World Health Organization (WHO) regions, with 600 million to 1 billion people at risk of infection.

While there is no human vaccine available yet, there have been numerous attempts and ongoing efforts to develop one. Traditional knowledge about "leishmanization," the practice of inoculation with live Leishmania to induce mild cutaneous leishmaniasis and prevent future dangerous infections, has informed vaccine development. Attempts have been made to create vaccines with live, inactivated, or attenuated Leishmania, but these have not been successful in humans. Other approaches using immunogenic recombinant Leishmania proteins or polyproteins, powerful Th1 adjuvants, and immunogenic surface antigens of Leishmania parasites have shown promise in animal models but have not yet proven effective in humans.

Several vaccines have advanced to clinical trials. One trial in Brazil tested an inactivated vaccine for human immunotherapy, while another in Uzbekistan used an attenuated vaccine. These trials have contributed significantly to increasing knowledge about human leishmaniasis immunology. However, an efficacious prophylactic human vaccine has not yet been identified.

The development of a vaccine is challenging due to the need to translate findings from animal models to clinical settings and transition products from the laboratory to the field. Additionally, the current control measures for leishmaniasis rely heavily on chemotherapy, which is associated with severe toxic side effects and increasing parasite drug resistance. This underscores the urgency of developing an effective vaccine to prevent and treat leishmaniasis.

Treatment: early diagnosis and prompt treatment reduce prevalence of the disease

Leishmaniasis is a parasitic disease caused by infection with Leishmania parasites, which are spread by the bite of infected sand flies. There are several different forms of leishmaniasis, the most common being cutaneous leishmaniasis (CL), which causes skin sores. Mucosal leishmaniasis (ML) is a severe type of CL that can cause sores in the nose, mouth, or throat and can be life-threatening. Another form is visceral leishmaniasis (VL), which affects the internal organs and can be deadly if left untreated.

Currently, there are no vaccines or drugs to prevent leishmaniasis in humans. The best way to prevent infection is to protect oneself from sand fly bites. However, even if one has had leishmaniasis before, it is possible to contract it again, so consistent prevention is crucial. If an individual suspects they may have leishmaniasis, they should seek medical advice, and tissue samples or bone marrow may be tested for diagnosis.

While there is no human vaccine, there has been success in developing a vaccine for dogs, providing them with immunity. This is significant as dogs are potential reservoirs for parasite transmission. In addition, there are several vaccines in development, and some have progressed to clinical trials. For instance, one clinical trial in Brazil utilised an inactivated vaccine for human immunotherapy, while another in Uzbekistan employed an attenuated vaccine.

The development of an effective human vaccine is imperative, given the global burden of leishmaniasis, with 600 million to 1 billion people at risk of infection. Furthermore, the disease is listed as a Neglected Tropical Disease by the World Health Organization, and it is associated with high mortality and morbidity rates, especially in children under five years of age.

Although an efficacious human vaccine is yet to be identified, recent advancements and increasing knowledge in immunology have contributed significantly to vaccine development. For instance, studies have demonstrated the safety of certain vaccines and their ability to induce reasonable immunogenicity and some protection. Additionally, traditional practices like "leishmanization", where inoculation with live Leishmania induces mild CL to prevent future dangerous infections, have informed vaccine development. Furthermore, the observation that individuals who recover from Leishmania infections develop lifelong immunity provides a strong basis for the feasibility of prophylactic vaccination.

Research: ongoing to develop human vaccines

Leishmaniasis is a parasitic disease caused by infection with Leishmania parasites, which are spread by the bite of infected sand flies. It is a neglected tropical disease (NTD) that affects people in tropical and subtropical regions of the world. There is currently no vaccine or drug available to prevent leishmaniasis in humans, and the best way to prevent infection is to protect oneself from sand fly bites.

However, research is ongoing to develop an effective human vaccine for leishmaniasis. The concept of a leishmaniasis vaccine is supported by the observation that most individuals who recover from the infection become resistant to future clinical infections. Traditional knowledge about "leishmanization"—the practice of inoculation with live Leishmania to induce mild cutaneous leishmaniasis to prevent future dangerous infections—has informed the development of a vaccine. Attempts to create a vaccine with live, inactivated, or attenuated Leishmania have failed, and while peptide, DNA, or protein vaccines have shown efficacy in animal models, they have not been effective in humans.

Recent advances in understanding the immunoregulatory mechanisms that suppress parasite-specific CD4+ T-cell responses in human visceral leishmaniasis (VL) patients have been made, and several vaccines are in development, with a few having progressed to clinical trials. One clinical trial in Brazil tested an inactivated vaccine for human immunotherapy, while another in Uzbekistan tested an attenuated vaccine. Other approaches include using immunogenic surface antigens of Leishmania parasites as vaccine candidates, with data from mouse and hamster models suggesting that protection against leishmaniasis can be achieved with defined candidate proteins.

The development of a vaccine using CRISPR-Cas9 technology was published in 2020, which showed that inoculation with a live attenuated Leishmania major strain induces durable protection. Another gene deletion mutant was created in a Leishmania mexicana strain in 2022, showing complete inhibition of the typical cutaneous lesions in mouse models. While these studies have demonstrated the safety of the vaccines and shown reasonable immunogenicity and some indication of protection, an efficacious prophylactic vaccine for humans is yet to be identified.

Frequently asked questions